Summary of HR 1262: Give Kids a Chance Act of 2025

Purpose and Intent

The Give Kids a Chance Act of 2025 aims to enhance research and development of treatments for pediatric cancers by amending the Federal Food, Drug, and Cosmetic Act. The bill focuses on improving the availability of molecularly targeted therapies for children and ensuring that pediatric studies are conducted in a timely and effective manner.

Key Provisions

The bill includes several significant provisions:

1. Molecularly Targeted Pediatric Cancer Investigations:

   • Establishes requirements for the investigation of drugs specifically for pediatric cancers, ensuring that studies yield meaningful data on dosing, safety, and efficacy tailored for children.

2. Completion of Pediatric Study Requirements:

   • Mandates that pharmaceutical companies complete pediatric studies as part of the drug approval process, ensuring that pediatric populations are considered in drug development.

3. Priority Review Vouchers:

   • Extends the authority to issue priority review vouchers for treatments targeting rare pediatric diseases, incentivizing pharmaceutical companies to invest in these areas.

4. Limitations on Orphan Drug Exclusivity:

   • Introduces limitations on the exclusive approval or licensure of orphan drugs, which are typically granted to drugs developed for rare diseases, to encourage more competition and access.

5. Transparency in Generic Drug Applications:

   • Increases transparency in the application process for generic drugs, facilitating quicker access to affordable medications for pediatric patients.

6. Organ Procurement and Transplantation Network:

   • Addresses issues related to organ procurement and transplantation, ensuring that pediatric needs are prioritized within these systems.

7. Establishment of the Abraham Accords Office:

   • Creates an office within the FDA to promote collaboration and research initiatives stemming from the Abraham Accords, potentially enhancing international cooperation in pediatric health.

Affected Parties

• Children with Cancer: The primary beneficiaries of this legislation will be pediatric patients suffering from cancer, who will gain access to more targeted and effective treatments.
• Pharmaceutical Companies: The bill places new requirements on drug manufacturers, particularly regarding pediatric studies, but also offers incentives through priority review vouchers.
• Healthcare Providers: Medical professionals will have access to a broader range of approved treatments for pediatric patients, improving care options.

Procedural Aspects

• Introduced: February 12, 2025
• Reported (Amended): October 31, 2025, by the Committee on Energy and Commerce (H. Rept. 119-352).
• Current Status: The bill has been placed on the Union Calendar and is awaiting further action in the House.

Conclusion

The Give Kids a Chance Act of 2025 represents a significant step towards improving the landscape of pediatric cancer treatment in the United States. By focusing on molecularly targeted therapies and ensuring that pediatric needs are prioritized in drug development, this legislation aims to provide children with better treatment options and outcomes.